Large Volume Parenteral (LVP) Market is Segmented By Volume(250 ml - 500 ml, 100 ml - 250 ml, 500 ml - 1000 ml, 1000 ml - 2000 ml), By Application( Nutritious Injections, Vitamin B12, Isolyte M in Dextrose, Fluid Balance Injections, Hypertonic Saline (3% and 5% Sodium Chloride Injection, 5% Dextrose and Electrolyte, Therapeutic Injection), By Type of Packaging(Bottles, Bags), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Large Volume Parenteral (LVP) Market Overview
Large Volume Parenteral (LVP) Market is expected to reach high CAGR of 3.1% over the forecast period (2023-2030). Large volume parenteral (LVPs) include intravenous solutions sold in bags or bottles of 100 mL or greater (250 mL, 500 mL, 1L). Common LVP has the keys needed to correct the electrolyte and fluid imbalances. They provide essential nutrients or act as a vehicle for delivering other drugs.
Large Volume Parenteral (LVP) Market Summary and Scope
|
Metrics |
Details |
|
Market CAGR |
3.1% |
|
Segments Covered |
By Volume, By Application, By Type of Packaging, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Large Volume Parenteral (LVP) Market Dynamics and Trends
The increasing demand for safer, faster, and most effective methods for drug administration in patients and increasing acceptance of single-dose vaccines is expected to drive market growth in the forecast period.
Increasing acceptance of single-dose vaccines is expected to drive the market in the forecast period.
Single-dose vaccines are ideal for maximizing vaccination coverage, helping stakeholders significantly reduce the costs associated with vaccination, and improving patient convenience. In addition, these vaccines might also help to decrease the expenses associated with multi-dose regimens and improve patient comfort, as fewer injections and healthcare visits will be needed to provide immunity, especially in specific target populations that require quick and protective immune responses, including travelers, patients expecting imminent surgery, and during outbreaks.
For instance, on February 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 disease in individuals 18 years of age and older.
Challenges in formulating large volume parenteral are expected to hamper the large global volume parenteral (LVP) market.
Achieving drug substance and excipient compatibility is the main challenge with parenteral dosage forms (that is, by eliminating the impurities formation by degradation of the drug substance or by the construction of a new chemical entity between the drug substance and the excipients) as well as avoiding leaching/adsorption issues in the preparation and the primary container. Whereas in solutions, the drug substances should be soluble and remain soluble during the entire shelf-life of the drug product. If the drug substances are poorly soluble, dissolution can be achieved using co-solvents, surfactants, a soluble pro-drug, or a solubility enhancer such as a cyclodextrin from an inclusion complex. The pH value should be as close to physiological levels as possible as it is one of the critical aspects of parenteral preparations. Another crucial issue that formulators face during drug development is the stability of the drug substance.
For instance, ample volume preparations (LVPs), defined as greater than 100 mL, should not contain a pH buffer; blood provides a buffer effect that could compete with the injected drug product. Hence, the challenges associated with parenteral manufacturing are expected to hamper the market growth.
COVID-19 Impact Analysis on Large Volume Parenteral (LVP) Market
COVID-19 positively impacted the extensive global volume parenteral (LVP) market. With the demand for COVID-19 vaccines, the need for large volume parenteral (LVP) has also increased and will drive market growth. For instance, amid these developments, a U.K. study has found a single dose of either the Oxford/B. Braun Melsungen AG or Pfizer/BioNTech vaccines have been found to cut Covid-19 transmission rates by up to half.
Large Volume Parenteral (LVP) Market Segment Analysis
250 ml - 500 ml large volume parenteral (LVP) segment dominated the market
Large Volume Parenteral (LVP) or simply LVPs- are sterile preparations of 250 ml or greater administered parenterally. For instance, the most common LVPs are IV solutions compounded from a standard/base solution, such as 0.9% sodium chloride (known as N.S., too), dextrose 5% in water (D5W), dextrose 5% in normal saline (D5NS), and Lactate Ringer (L.R.) solution. Large volume parenteral (LVPs) include intravenous solutions sold in bags or bottles containing 100 mL or greater (250 mL, 500 mL, 1 L). Larger quantities are typically required, packaged in these large volumes. Common LVP includes solutions needed to correct electrolyte and fluid imbalances, provide essential nutrients or act as a vehicle for the delivery of other drugs. Increased reference for single-dose administration of vaccines and medicines, growing demand for a faster route of drug administration to avoid complications is expected to drive the need for the large global volume parenteral (LVP) market.
Nutritious injections are expected to drive the market in the forecast period.
Vitamin injections are viral, and for a good reason. They help or vastly improve an individual's overall health and well-being safely and effectively. For instance, when these vital nutrients are injected directly into the body, they are immediately available for absorption, providing a fast way to benefit from the vitamins and minerals. This technique is precious for people who suffer from G.I. issues that prevent the proper absorption of oral supplements. However, anyone can benefit from nutrient injections. People see nutrient injections to deal with anxiety/depression, lack of energy, beauty benefits, enhanced athletic performance, and overall health and well-being.
For instance, on January 28, 2020, American Regent launched Zinc Sulfate Injection, a trace element indicated as a source of zinc for parenteral nutrition in adult and pediatric patients when oral or enteral nutrition is not possible, insufficient, or contraindicated. First, FDA approved Zinc Sulfate Injectiondeveloped to align with the American Society for Parenteral and Enteral Nutrition (ASPEN) recommendations for trace element supplementation.
Large Volume Parenteral (LVP) Market Geographical Analysis
North America is expected to hold the largest market share in the large global volume parenteral (LVP) market.
The government's high research expenditure in the healthcare sector, technological advancements, and new products in this region are expected to dominate the sizeable global volume parenteral (LVP) market. Approximately 740 units of normal saline are used in this region every minute, which covers the regional growth of the need for large volume parenteral. Furthermore, favorable reimbursement policies have resulted in an increase in hospital admissions, which is expected to boost usage rates in this region. For instance, the reimbursement scenario for IV nutrition appears to be promising. In the United States, Medicare covers up to 80% of the costs of parenteral and enteral nutrition, including medical equipment, physician services, and other related medical services, benefiting patients.
Large Volume Parenteral (LVP) Companies and Competitive Landscape
The sizeable global volume parenteral (LVP) market is highly competitive with increasing demand for large volume parenteral, product launches by companies, and company mergers. Some of the companies which are present in the large global volume parenteral (LVP) market are B. Braun Melsungen AG, Baxter Healthcare Corporation, Fresenius Kabi AG, Pfizer, Inc., BML Parenteral Drugs, Emcure Pharmaceuticals Ltd, Otsuka Pharmaceutical Factory, Inc., Beximco Pharma, China Resources Pharmaceutical GroupCo., Ltd. and Ozon Pharmaceuticals.
Baxter Healthcare Corporation
Overview: American multinational health care company Baxter International Inc. has its headquarters in Deerfield, Illinois. The company product portfolio includes products that help treat hemophilia, kidney disease, immune disorders, other chronic and acute medical conditions.
Product Portfolio: The company manufactures IV Solutions and Irrigation Solutions. The IV solutions include Dextrose for Injection, Dextrose & Sodium Chloride for Injection, Lactated Ringer's & Ringer's for Injection, PLASMALYTE (Multiple Electrolyte) Injections, Sodium Chloride Injections, Potassium Chloride in Dextrose & Sodium Chloride Injections and Sterile Water for Injection.
Critical Development: On September 23, 2020, Baxter International Inc received U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix (amino acids in dextrose) Injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) Injections. These new linimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S., making it easier to reach patient protein targets while delivering less fluid and dextrose than provided by existing formulations.
